ATE440284T1 - Verwendung von adiponectin zur diagnose von krebs - Google Patents
Verwendung von adiponectin zur diagnose von krebsInfo
- Publication number
- ATE440284T1 ATE440284T1 AT04701189T AT04701189T ATE440284T1 AT E440284 T1 ATE440284 T1 AT E440284T1 AT 04701189 T AT04701189 T AT 04701189T AT 04701189 T AT04701189 T AT 04701189T AT E440284 T1 ATE440284 T1 AT E440284T1
- Authority
- AT
- Austria
- Prior art keywords
- cancer
- adiponectin
- disclosed
- epithelial
- methods
- Prior art date
Links
- 102000011690 Adiponectin Human genes 0.000 title abstract 4
- 108010076365 Adiponectin Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 201000009030 Carcinoma Diseases 0.000 abstract 3
- 206010014733 Endometrial cancer Diseases 0.000 abstract 3
- 206010014759 Endometrial neoplasm Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 238000003745 diagnosis Methods 0.000 abstract 2
- 229940124232 Adiponectin receptor agonist Drugs 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43908803P | 2003-01-09 | 2003-01-09 | |
| PCT/US2004/000410 WO2004063711A2 (en) | 2003-01-09 | 2004-01-09 | Use of adiponectin to diagnose and treat malignancy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE440284T1 true ATE440284T1 (de) | 2009-09-15 |
Family
ID=32713428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04701189T ATE440284T1 (de) | 2003-01-09 | 2004-01-09 | Verwendung von adiponectin zur diagnose von krebs |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1585987B1 (de) |
| AT (1) | ATE440284T1 (de) |
| DE (1) | DE602004022632D1 (de) |
| WO (1) | WO2004063711A2 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE554393T1 (de) * | 2003-09-27 | 2012-05-15 | Siemens Healthcare Diagnostics | Diagnostika und therapeutika für mit adiponectin receptor 2 (adipor2) assoziierten erkrankungen |
| JP5386056B2 (ja) * | 2003-11-04 | 2014-01-15 | 第一三共株式会社 | 抗腫瘍剤 |
| US7592423B2 (en) | 2005-01-07 | 2009-09-22 | Xencor, Inc. | Globular adiponectin variants |
| US7678886B2 (en) | 2005-01-07 | 2010-03-16 | Xencor, Inc. | Pharmaceutical compositions of adiponectin variants and methods of storage |
| US7749956B2 (en) | 2005-01-07 | 2010-07-06 | Xencor, Inc. | Method of treatment using adiponectin variants |
| US8093017B2 (en) | 2005-12-07 | 2012-01-10 | Siemens Heathcare Diagnostics Inc. | Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics |
| CN101932728B (zh) | 2007-11-30 | 2013-06-19 | 西门子医疗保健诊断公司 | 脂连蛋白受体片段和使用方法 |
| US8865648B2 (en) * | 2009-04-23 | 2014-10-21 | Siemens Healthcare Diagnostics Inc. | Monomeric and dimeric forms of adiponectin receptor fragments and methods of use |
| KR102402428B1 (ko) * | 2021-06-18 | 2022-05-31 | 주식회사 레지온 | 난소암 진단용 다중 바이오 마커 및 이의 용도 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002546A1 (en) * | 1997-07-08 | 1999-01-21 | Human Genome Sciences, Inc. | 123 human secreted proteins |
| FR2767135B1 (fr) * | 1997-08-06 | 2002-07-12 | Genset Sa | Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes |
| JPWO2002061076A1 (ja) * | 2001-02-01 | 2004-06-03 | 持田製薬株式会社 | アディポネクチン関連蛋白質 |
-
2004
- 2004-01-09 DE DE602004022632T patent/DE602004022632D1/de not_active Expired - Lifetime
- 2004-01-09 AT AT04701189T patent/ATE440284T1/de not_active IP Right Cessation
- 2004-01-09 WO PCT/US2004/000410 patent/WO2004063711A2/en not_active Ceased
- 2004-01-09 EP EP04701189A patent/EP1585987B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004063711A2 (en) | 2004-07-29 |
| EP1585987A2 (de) | 2005-10-19 |
| WO2004063711A3 (en) | 2004-09-16 |
| DE602004022632D1 (de) | 2009-10-01 |
| EP1585987B1 (de) | 2009-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Di Palma et al. | Salivary duct carcinomas can be classified into luminal androgen receptor‐positive, HER2 and basal‐like phenotypes | |
| WO2006089212A3 (en) | Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin | |
| DE60214134D1 (de) | Modifizierte psma-liganden und deren verwendung | |
| DE602006018578D1 (de) | Diagnose- und prognoseverfahren von blasenkrebs. | |
| ATE365922T1 (de) | Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6) | |
| CA2701341A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| Hwang et al. | Prognostic influence of BCL2 on molecular subtypes of breast cancer | |
| ATE440284T1 (de) | Verwendung von adiponectin zur diagnose von krebs | |
| Tsang et al. | Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer | |
| Gadducci et al. | Is perineural invasion a novel prognostic factor useful to tailor adjuvant treatment in patients treated with primary surgery for cervical and vulvar carcinoma? | |
| Kachrilas et al. | PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer | |
| ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
| ATE430936T1 (de) | Verwendung von cyfra 21-1 und osteopontin als marker für kolorektalkarzinome | |
| MX2012007009A (es) | Método para diagnosticar un tumor maligno. | |
| DK2199801T3 (da) | Biomarkører til tidlig påvisning af ovariecancer | |
| WO2020204373A3 (ko) | 고형암 진단 장치와 고형암 진단 정보 제공 방법 | |
| ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
| ATE459883T1 (de) | Neue proliferationsmarker in der klinischen praxis und deren verwendung zur krebsprognose oder -diagnose | |
| WO2006078911A3 (en) | Gitr antibodies for the diagnosis of nsclc | |
| Mhawech-Fauceglia et al. | Role of the tumour necrosis family ligand APRIL in solid tumour development: Retrospective studies in bladder, ovarian and head and neck carcinomas | |
| Ciesielska et al. | Comparison of TMA technique and routine whole slide analysis in evaluation of proliferative markers expression in laryngeal squamous cell cancer | |
| EP1539818A4 (de) | Zusammensetzungen und deren verwendungen zur identifizierung und zum targetting von provasopressinexprimierenden krebszellen | |
| Hwang et al. | A study on the relationships between osteoporosis knowledge, self-efficacy and health belief of women in an island | |
| ATE353544T1 (de) | Verwendung des proteins masp als marker für kolorektale karzinome | |
| ATE394676T1 (de) | Verbindungen und verfahren zur diagnose von prostatakrebs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |